(Sharecast News) - Biopharma giant GSK has announced that Japanese regulators have expanded the approved use of its Arexvy vaccine for severe respiratory syncytial virus (RSV) disease to a wider ...

GSK (GSK) announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV disease to ...

(RTTNews) - GSK plc (GSK, GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV ...

GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indication of Arexvy (respiratory syncytial virus vaccine, recombinant ...

GSK's RSV vaccine Arexvy has been approved in Japan for adults aged 60 and over since September last year for the prevention of the disease caused by RSV, a common contagious virus that affects ...

All are formulated to protect against two subtypes of the virus, A and B. Arexvy In May 2023, Arexvy, from GSK, became the first vaccine approved by the U.S. Food and Drug Administration (FDA ...

Arexvy, the first RSV vaccine approved in the country for this age group, is currently authorised in the US and a further 35 countries. The vaccine's active ingredient is a recombinant RSV ...

In June, the FDA expanded the approval of GSK's RSV vaccine (Arexvy) for use in adults ages 50 to 59 at risk of RSV-related lower respiratory tract disease due to underlying conditions ...

GSK’s third-quarter Vaccine sales declined 15% due to lower sales of its RSV vaccine Arexvy and shingles vaccine, Shingrix. Arexvy generated £188 million during the quarter, down 72% year over ...